Origenis Extends Collaboration and Licensing Agreement with Major Pharmaceutical Company
News May 02, 2013
The alliance combines Origenis' capabilities in compound design, chemical synthesis, and screening with the collaborator’s applied biology, pharmacology, and development expertise in therapeutics.
During the long standing collaboration, Origenis successfully employed its proprietary small molecule discovery platform MOREsystem® to design, synthesize, and characterize novel molecules acting against different targets. Under the extended agreement, Origenis will deliver development candidates with defined properties for certain targets.
Dr. Michael Thormann, Managing Director at Origenis said: “This new agreement underlines the quality of the compounds transferred in the past and the power of our technology platform as well as our interdisciplinary approach and expertise applied to development compounds and commitment of our company in the small molecule drug sector.”
Under the terms of the agreement, the collaborator will receive rights to develop products against defined molecular targets for any indication. Origenis will receive research payments and is eligible for certain development milestones and also royalties on sales.
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017